share_log

Altimmune | 3: Initial statement of beneficial ownership of securities-Officer Shutterly Andrew

Altimmune | 3: Initial statement of beneficial ownership of securities-Officer Shutterly Andrew

Altimmune | 3:首次持股聲明-高管 Shutterly Andrew
美股sec公告 ·  07/01 18:04
Moomoo AI 已提取核心訊息
Andrew Shutterly, the Acting Chief Financial Officer of Altimmune, Inc., filed an Initial Statement of Beneficial Ownership of Securities with the SEC on July 1, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Shutterly's direct ownership of 10,113 shares of common stock and various derivative securities, including stock options and restricted stock units (RSUs). The stock options have exercise prices ranging from $4.48 to $12.88 and vesting periods extending up to 2034. The RSUs are set to vest in annual installments through 2027, contingent upon Shutterly's continued service. This filing provides transparency into the holdings of Altimmune's executives and is a routine disclosure for investors monitoring insider transactions.
Andrew Shutterly, the Acting Chief Financial Officer of Altimmune, Inc., filed an Initial Statement of Beneficial Ownership of Securities with the SEC on July 1, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Shutterly's direct ownership of 10,113 shares of common stock and various derivative securities, including stock options and restricted stock units (RSUs). The stock options have exercise prices ranging from $4.48 to $12.88 and vesting periods extending up to 2034. The RSUs are set to vest in annual installments through 2027, contingent upon Shutterly's continued service. This filing provides transparency into the holdings of Altimmune's executives and is a routine disclosure for investors monitoring insider transactions.
Altimmune的臨時財務長Andrew Shutterly於2024年7月1日向SEC提交了一份初始有利所有權聲明。根據證券交易法案第16(a)條的規定,提交的文件詳細描述了Shutterly對10113股普通股和各種衍生證券的直接所有權,包括股票期權和限制性股票單元(RSUs)。股票期權的行權價格在$4.48至$12.88之間,行權期延伸至2034年。RSUs將在2027年逐年分期歸屬,取決於Shutterly的繼續服務。此提交提供了關於Altimmune高管持股的透明度,並且是監控內部交易的投資者的例行披露。
Altimmune的臨時財務長Andrew Shutterly於2024年7月1日向SEC提交了一份初始有利所有權聲明。根據證券交易法案第16(a)條的規定,提交的文件詳細描述了Shutterly對10113股普通股和各種衍生證券的直接所有權,包括股票期權和限制性股票單元(RSUs)。股票期權的行權價格在$4.48至$12.88之間,行權期延伸至2034年。RSUs將在2027年逐年分期歸屬,取決於Shutterly的繼續服務。此提交提供了關於Altimmune高管持股的透明度,並且是監控內部交易的投資者的例行披露。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息